{"id":10546,"date":"2019-11-02T13:56:46","date_gmt":"2019-11-02T08:26:46","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=10546"},"modified":"2026-07-08T21:54:46","modified_gmt":"2026-07-08T16:24:46","slug":"adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/","title":{"rendered":"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial"},"content":{"rendered":"<div class=\"wp-block-image wp-image-10553\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"138\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/ADC-Therapeutics-Market-Daiichi-Sankyo-Logo-Roots.webp\" alt=\"\" class=\"wp-image-17521\" style=\"object-fit:contain;width:557px;height:100px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/ADC-Therapeutics-Market-Daiichi-Sankyo-Logo-Roots.webp 768w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/ADC-Therapeutics-Market-Daiichi-Sankyo-Logo-Roots-300x54.webp 300w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/><figcaption class=\"wp-element-caption\">Daiichi Sankyo<\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">On October 31, 2019,&nbsp;Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04145622\">NCT04145622<\/a>) evaluating <a href=\"https:\/\/www.daiichisankyo.com\/media_investors\/investor_relations\/ir_calendar\/files\/005443\/Conference%20Call%20Materials.pdf\">DS-7300<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What is DS-7300<\/strong>? <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">DS-7300 is an investigational B7-H3 targeting antibody-drug conjugate (ADC).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What is B7-H3<\/strong>?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">It is a\u00a0Type I transmembrane protein belonging to the B7 family, which includes immune checkpoint molecules such as CTLA-4 ligands, and PD-L1. The protein is more highly expressed in various solid cancers, compared to normal tissues. Overexpression of B7-H3 is associated with poor prognosis in some solid cancers including NSCLC and prostate cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In what patient segment is the drug being evaluated:<\/strong> The drug is being developed for the treatment of patients with advanced solid malignant tumors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Where is the trial being conducted:&nbsp;<\/strong>The trial is being conducted in the US and Japan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>How many patients are expected to be enrolled:<\/strong> A total of approximately 160 patients are expected to be enrolled in this study.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read the complete story Daiichi Sankyo <a href=\"https:\/\/pipelinereview.com\/index.php\/2019103172734\/Antibodies\/Daiichi-Sankyo-Initiates-Clinical-Trial-with-its-4th-DXd-Antibody-Drug-Conjugate-DS-7300-in-Collaboration-with-Sarah-Cannon-Research-Institute.html\">here<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How many ADCs are being developed for solid tumors<\/strong>?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">As per a recent report by Roots Analysis, currently, more than 240 ADCs are being developed across various clinical\/preclinical stages. The majority of clinical ADCs are being developed for the treatment of patients with solid tumors.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"352\" src=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/ADC-Therapeutics-Market-Clinical-Pipeline-Roots.webp\" alt=\"Antibody Drug Conjugates Pipeline based on the analysis done by Roots\" class=\"wp-image-17523\" style=\"object-fit:contain;width:800px;height:352px\" srcset=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/ADC-Therapeutics-Market-Clinical-Pipeline-Roots.webp 768w, https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2023\/10\/ADC-Therapeutics-Market-Clinical-Pipeline-Roots-300x138.webp 300w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">With such a strong development pipeline, the overall ADC therapeutics market is projected to be worth&nbsp;<a href=\"https:\/\/www.rootsanalysis.com\/reports\/antibody-drug-conjugates-market\/270.html\">$15 billion by 2030, growing at a CAGR of over 20%<\/a><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/antibody-drug-conjugates-market-5th-edition-2019-2030\/270.html\">.<\/a>&nbsp;This fast-growing market offers immense opportunities for contract manufacturers, service providers, and technology developers.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On October 31, 2019,&nbsp;Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study (NCT04145622) evaluating DS-7300. What is DS-7300? DS-7300 is an investigational B7-H3 targeting antibody-drug conjugate (ADC). What is B7-H3? It is a\u00a0Type I transmembrane protein belonging to the B7 family, which includes immune [&hellip;]<\/p>\n","protected":false},"author":21,"featured_media":17257,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[291],"tags":[322,165],"class_list":["post-10546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-adcs-pipeline","tag-adcs-pipeline","tag-antibody-drug-conjugates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial | Blog<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial | Blog\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RootsAnalysis\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-02T08:26:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-08T16:24:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_Logo.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"150\" \/>\n\t<meta property=\"og:image:height\" content=\"150\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Gaurav Chaudhary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:site\" content=\"@RootsAnalysis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gaurav Chaudhary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/\"},\"author\":{\"name\":\"Gaurav Chaudhary\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\"},\"headline\":\"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial\",\"datePublished\":\"2019-11-02T08:26:46+00:00\",\"dateModified\":\"2026-07-08T16:24:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/\"},\"wordCount\":261,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_Logo.webp\",\"keywords\":[\"ADCs Pipeline\",\"Antibody Drug Conjugates\"],\"articleSection\":[\"ADCs Pipeline\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/\",\"name\":\"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial | Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_Logo.webp\",\"datePublished\":\"2019-11-02T08:26:46+00:00\",\"dateModified\":\"2026-07-08T16:24:46+00:00\",\"description\":\"Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\\\/2 study..\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_Logo.webp\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2019\\\/11\\\/RootsAnalysis_FeaturedImage_Logo.webp\",\"width\":150,\"height\":150,\"caption\":\"This is a feature image for blog article Daiichi Sankyo ADC Pipeline Update at Roots Analysis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"name\":\"Blog\",\"description\":\"Roots Analysis\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#organization\",\"name\":\"Roots Analysis\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/11\\\/Roots-Analysis-High-Resolution-Logo.jpg\",\"width\":205,\"height\":61,\"caption\":\"Roots Analysis\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/RootsAnalysis\\\/\",\"https:\\\/\\\/x.com\\\/RootsAnalysis\",\"https:\\\/\\\/www.instagram.com\\\/rootsanalysis\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/roots-analysis\\\/\",\"https:\\\/\\\/www.pinterest.it\\\/analysis1340\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCwZF57vY1lnU0bNLej2zukg\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rootsanalysis.com\\\/blog\\\/#\\\/schema\\\/person\\\/e8e0ebc31296140424e1e7fcc11331bc\",\"name\":\"Gaurav Chaudhary\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g\",\"caption\":\"Gaurav Chaudhary\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial | Blog","description":"Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial | Blog","og_description":"Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study..","og_url":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/","og_site_name":"Blog","article_publisher":"https:\/\/www.facebook.com\/RootsAnalysis\/","article_published_time":"2019-11-02T08:26:46+00:00","article_modified_time":"2026-07-08T16:24:46+00:00","og_image":[{"width":150,"height":150,"url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_Logo.webp","type":"image\/webp"}],"author":"Gaurav Chaudhary","twitter_card":"summary_large_image","twitter_creator":"@RootsAnalysis","twitter_site":"@RootsAnalysis","twitter_misc":{"Written by":"Gaurav Chaudhary","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/"},"author":{"name":"Gaurav Chaudhary","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc"},"headline":"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial","datePublished":"2019-11-02T08:26:46+00:00","dateModified":"2026-07-08T16:24:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/"},"wordCount":261,"publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_Logo.webp","keywords":["ADCs Pipeline","Antibody Drug Conjugates"],"articleSection":["ADCs Pipeline"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/","url":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/","name":"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial | Blog","isPartOf":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_Logo.webp","datePublished":"2019-11-02T08:26:46+00:00","dateModified":"2026-07-08T16:24:46+00:00","description":"Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1\/2 study..","breadcrumb":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#primaryimage","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_Logo.webp","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2019\/11\/RootsAnalysis_FeaturedImage_Logo.webp","width":150,"height":150,"caption":"This is a feature image for blog article Daiichi Sankyo ADC Pipeline Update at Roots Analysis"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rootsanalysis.com\/blog\/adcs-pipeline-update-daiichi-sankyo-initiates-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rootsanalysis.com\/blog\/"},{"@type":"ListItem","position":2,"name":"ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.rootsanalysis.com\/blog\/#website","url":"https:\/\/www.rootsanalysis.com\/blog\/","name":"Blog","description":"Roots Analysis","publisher":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rootsanalysis.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rootsanalysis.com\/blog\/#organization","name":"Roots Analysis","url":"https:\/\/www.rootsanalysis.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","contentUrl":"https:\/\/www.rootsanalysis.com\/blog\/wp-content\/uploads\/2018\/11\/Roots-Analysis-High-Resolution-Logo.jpg","width":205,"height":61,"caption":"Roots Analysis"},"image":{"@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RootsAnalysis\/","https:\/\/x.com\/RootsAnalysis","https:\/\/www.instagram.com\/rootsanalysis\/","https:\/\/www.linkedin.com\/company\/roots-analysis\/","https:\/\/www.pinterest.it\/analysis1340\/","https:\/\/www.youtube.com\/channel\/UCwZF57vY1lnU0bNLej2zukg"]},{"@type":"Person","@id":"https:\/\/www.rootsanalysis.com\/blog\/#\/schema\/person\/e8e0ebc31296140424e1e7fcc11331bc","name":"Gaurav Chaudhary","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1661cbb4c9924618db626ec780a3daf2ebd251e93753c083102682dba715ded6?s=96&d=mm&r=g","caption":"Gaurav Chaudhary"}}]}},"_links":{"self":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/comments?post=10546"}],"version-history":[{"count":5,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10546\/revisions"}],"predecessor-version":[{"id":22336,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/posts\/10546\/revisions\/22336"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media\/17257"}],"wp:attachment":[{"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/media?parent=10546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/categories?post=10546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rootsanalysis.com\/blog\/wp-json\/wp\/v2\/tags?post=10546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}